Drug Trial Radar · NCT00144170
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
882
Actual
Start
Feb 2003
Primary completion
Oct 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients. Patients must have a viral load \> =1000 cells/mL, and genotype indicating at least one resistance conferring protease inhibitor-mutation as determined from a predefined panel of mutations. Any CD4+ count is acceptable.
Conditions
- HIV Infections
Interventions
Tipranavir (with low dose ritonavir)Drug
Comparator protease inhibitor(CPI)/low dose ritonavir(r)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Response at Week 48Time frame: after 48 weeks of treatment
- Time to Treatment Failure Through 48 Weeks of TreatmentTime frame: after 48 weeks of treatment
Locations
174 sites in 17 countries. Site status is shown where the registry gives one.
1182.48.5401 Fundación Huésped
Buenos Aires, Argentina
1182.48.5402 Fundación Huésped
Buenos Aires, Argentina
1182.48.5403 Servicio de Infecciosas
Buenos Aires, Argentina
1182.48.5404 Servicio de Infecciosas
Buenos Aires, Argentina
1182.48.5405 Hospital Muniz
Buenos Aires, Argentina
1182.48.5406 Servicio de Immunocomprometido
Buenos Aires, Argentina
1182.48.4301 Boehringer Ingelheim Investigational Site
Vienna, Austria
1182.48.3209 Boehringer Ingelheim Investigational Site
Antwerp, Belgium
1182.48.3201 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1182.48.3202 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1182.48.3206 Boehringer Ingelheim Investigational Site
Charleroi, Belgium
1182.48.3207 Boehringer Ingelheim Investigational Site
Ghent, Belgium
1182.48.3210 Boehringer Ingelheim Investigational Site
Luxembourg, Belgium
1182.48.5512 Cidade Universitária Zeferino Vaz-Clínica Médica FCM
Campinas - SP, Brazil
1182.48.5505 Instituto A-Z de Pesquisa e Ensino da PUC
Curitiba - PR, Brazil
1182.48.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde
Nova Iguaçu - RJ, Brazil
1182.48.5502 Fundação Oswaldo Cruz
Rio de Janeiro - RJ, Brazil
1182.48.5509 Universidade Federal do Rio de Janeiro
Rio de Janeiro - RJ, Brazil
1182.48.5511 Universidade Federal da Bahia-Unidade Docente Assistencial d
Salvador - BA, Brazil
1182.48.5501 Clínica de Doenças Parasitárias e Infecciosas-Hospital Dia
São Paulo - SP, Brazil
1182.48.5503 I.I. Emilio Ribas - Moléstias Infecciosas
São Paulo - SP, Brazil
1182.48.5504 Hospital do Servidor Público Estadual - IAMSPE
São Paulo - SP, Brazil
1182.48.5506 Centro de Referência e Treinamento - DST/AIDS
São Paulo - SP, Brazil
1182.48.5508 I.I. Emilio Ribas
São Paulo - SP, Brazil
1182.48.5510 INCOR e Hospital das Clínicas da Universidade de São Paulo
São Paulo - SP, Brazil
1182.48.5513 UNIFESP - Centro de Pesquisa Clinica
São Paulo - SP, Brazil
1182.48.4505 Boehringer Ingelheim Investigational Site
Aarhus N, Denmark
1182.48.4502 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
1182.48.4501 Boehringer Ingelheim Investigational Site
København Ø, Denmark
1182.48.4504 Boehringer Ingelheim Investigational Site
Odense C, Denmark
1182.48.3311 Boehringer Ingelheim Investigational Site
Besançon, France
1182.48.3307 Boehringer Ingelheim Investigational Site
Bordeaux, France
1182.48.3317 Boehringer Ingelheim Investigational Site
Bordeaux, France
1182.48.3302 Boehringer Ingelheim Investigational Site
Caen, France
1182.48.3303 Boehringer Ingelheim Investigational Site
Clamart, France
1182.48.3305 Boehringer Ingelheim Investigational Site
Le Kremlin-Bicêtre, France
1182.48.3304 Boehringer Ingelheim Investigational Site
Lyon, France
1182.48.3322 Boehringer Ingelheim Investigational Site
Lyon, France
1182.48.3308 Boehringer Ingelheim Investigational Site
Marseille, France
1182.48.3309 Boehringer Ingelheim Investigational Site
Marseille, France
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.